A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients with NRAS-Mutant Advanced Melanoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503107-21-00

Acronym

GO42273

Enrollment

Registered

2023-11-30

Start date

2021-05-14

Completion date

2025-09-04

Last updated

2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NRAS-mutant advanced cutaneous melanoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Norway

None listed

Source: EU CTIS · Data processed: Feb 4, 2026